CRISPR Therapeutics

News

CRISPR Therapeutics begins natural killer cell cancer tie-up...

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer.

News

Vertex eyes controllable genetic drugs with $1.3bn Obsidian ...

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform.

News

Nobel winner Charpentier's CRISPR Therapeutics gets $900m in...

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell dis

News

Vertex, CRISPR prep filing for gene-editing blood disorder t...

Vertex Pharma and partner CRISPR Therapeutics will start a rolling marketing application in the US for their gene-editing drug for sickle cell disease (SCD) and beta thalassaemia later this

News

EHA: Vertex, CRISPR build case for gene-editing drug

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effec

News

ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disord...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage tr